CN109803679A - 在基因组重新编码生物体中生产硒代生物制剂 - Google Patents

在基因组重新编码生物体中生产硒代生物制剂 Download PDF

Info

Publication number
CN109803679A
CN109803679A CN201780053385.XA CN201780053385A CN109803679A CN 109803679 A CN109803679 A CN 109803679A CN 201780053385 A CN201780053385 A CN 201780053385A CN 109803679 A CN109803679 A CN 109803679A
Authority
CN
China
Prior art keywords
sequence
protein
variant form
selenocysteine
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780053385.XA
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·J·格雷格
丹尼尔·J·曼德尔
罗西·塞耶尔
安德鲁·D·埃林顿
彼得·本杰明·斯特兰杰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Harvard University
Original Assignee
University of Texas System
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Harvard University filed Critical University of Texas System
Publication of CN109803679A publication Critical patent/CN109803679A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780053385.XA 2016-08-30 2017-08-30 在基因组重新编码生物体中生产硒代生物制剂 Pending CN109803679A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381316P 2016-08-30 2016-08-30
US62/381,316 2016-08-30
US201762537986P 2017-07-28 2017-07-28
US62/537,986 2017-07-28
PCT/US2017/049354 WO2018045018A1 (en) 2016-08-30 2017-08-30 Production of seleno-biologics in genomically recoded organisms

Publications (1)

Publication Number Publication Date
CN109803679A true CN109803679A (zh) 2019-05-24

Family

ID=61301655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053385.XA Pending CN109803679A (zh) 2016-08-30 2017-08-30 在基因组重新编码生物体中生产硒代生物制剂

Country Status (5)

Country Link
US (1) US11492650B2 (https=)
EP (1) EP3506945A4 (https=)
JP (2) JP7186400B2 (https=)
CN (1) CN109803679A (https=)
WO (1) WO2018045018A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021203861A1 (zh) * 2020-04-10 2021-10-14 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN114144426A (zh) * 2019-04-19 2022-03-04 印地安纳大学理事会 餐时或基础胰岛素类似物通过内部二硒桥的稳定化
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11155804B2 (en) 2016-07-11 2021-10-26 Board Of Regents, The University Of Texas System Recombinant polypeptides comprising selenocysteine and method for producing the same
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
EP3821003A4 (en) * 2018-07-09 2022-07-20 Gro Biosciences Inc. Non-standard amino acid containing compositions and uses thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025222144A1 (en) * 2024-04-18 2025-10-23 Fred Hutchinson Cancer Center Antibodies and vaccines having vh3-21 and vl1-40 binding domains and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298212A1 (en) * 2007-11-20 2010-11-25 Ambrx, Inc. Modified Insulin Polypeptides and Their Uses
AU2012216723A1 (en) * 2007-11-20 2012-09-27 Ambrx, Inc. Modified insulin polypeptides and their uses
US20140024592A1 (en) * 2010-09-08 2014-01-23 Howard Florey Institute Of Experimental Physiology And Medicine Modified Relaxin Polypeptides
CN103619875A (zh) * 2011-01-28 2014-03-05 加拿大国家研究委员会 免疫球蛋白结构域的工程改造
US20140154744A1 (en) * 2011-07-11 2014-06-05 Yale University Compositions and Methods for Making Selenocysteine Containing Polypeptides
CN105111304A (zh) * 2015-09-30 2015-12-02 山东阿华生物药业有限公司 重组人胰岛素前体的纯化和酶切转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849417B1 (en) 1998-04-06 2005-02-01 The United States Of America As Represented By The Department Of Health And Human Services Mammalian selenoprotein differentially expressed in tumor cells
AU6987200A (en) 1999-08-16 2001-03-13 Karolinska Innovations Ab Methods and means for selenoprotein expression
WO2007075438A2 (en) 2005-12-15 2007-07-05 Codon Devices, Inc. Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Ｊｎｃ株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
US10240158B2 (en) 2011-07-11 2019-03-26 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10876142B2 (en) 2011-07-11 2020-12-29 Yale University Compositions and methods for making selenocysteine containing polypeptides
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
US20150050682A1 (en) 2013-08-15 2015-02-19 University Of Vermont And State Agricultural College Direct assay of thioredoxin reductase activity
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
US10118950B2 (en) 2014-08-30 2018-11-06 Northwestern University Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
US10557160B2 (en) 2015-12-15 2020-02-11 Board Of Regents, The University Of Texas System Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same
WO2018014091A1 (en) 2016-07-22 2018-01-25 University Of Utah Research Foundation Insulin analogs
US11155804B2 (en) 2016-07-11 2021-10-26 Board Of Regents, The University Of Texas System Recombinant polypeptides comprising selenocysteine and method for producing the same
BR112019000991A2 (pt) * 2016-07-22 2019-07-02 University Of Utah Research Foundation análogo da insulina, composição farmacêutica, método para tratar e/ou prevenir uma afeção relacionada com insulina, método para decrescer níveis de glicose no sangue, uso do análogo da insulina, método de replanejamento ou modificação de um polipeptídeo que é conhecido por se ligar a um receptor da insulina, polipeptídeo, molécula isolada, método para identificar um composto que se liga ao receptor de insulina, método de base computacional para identificar um composto que imita a atividade da insulina, composto identificado usando um método, cristal do polipeptídeo, estrutura do polipeptídeo, uso da estrutura, uso do modelo estrutural, peptídeo, método para aumentar a ativação do receptor da insulina em um sujeito, método para diminuir o açúcar no sangue em um sujeito, método para tratar diabetes tipo 1 em um sujeito e proteína terapêutica
US20220144915A1 (en) 2019-04-19 2022-05-12 The Trustees Of Indiana University Stabilization of prandial or basal insulin analogues by an internal diselenide bridge

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298212A1 (en) * 2007-11-20 2010-11-25 Ambrx, Inc. Modified Insulin Polypeptides and Their Uses
AU2012216723A1 (en) * 2007-11-20 2012-09-27 Ambrx, Inc. Modified insulin polypeptides and their uses
US20140024592A1 (en) * 2010-09-08 2014-01-23 Howard Florey Institute Of Experimental Physiology And Medicine Modified Relaxin Polypeptides
CN103619875A (zh) * 2011-01-28 2014-03-05 加拿大国家研究委员会 免疫球蛋白结构域的工程改造
US20140154744A1 (en) * 2011-07-11 2014-06-05 Yale University Compositions and Methods for Making Selenocysteine Containing Polypeptides
CN105111304A (zh) * 2015-09-30 2015-12-02 山东阿华生物药业有限公司 重组人胰岛素前体的纯化和酶切转换方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUIS MORODER: "Isosteric replacement of sulfur with other chalcogens in peptides and proteins", JOURNAL OF PEPTIDE SCIENCE, vol. 11, pages 205 *
QING-XIN HUA等: "Structure of a protein in a kinetic trap", NATURE STRUCTURAL BIOLOGY, vol. 2, pages 130 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144426A (zh) * 2019-04-19 2022-03-04 印地安纳大学理事会 餐时或基础胰岛素类似物通过内部二硒桥的稳定化
WO2021203861A1 (zh) * 2020-04-10 2021-10-14 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体

Also Published As

Publication number Publication date
JP2020502104A (ja) 2020-01-23
CA3034701A1 (en) 2018-03-08
JP7378106B2 (ja) 2023-11-13
US20190194713A1 (en) 2019-06-27
WO2018045018A8 (en) 2018-05-11
US11492650B2 (en) 2022-11-08
JP7186400B2 (ja) 2022-12-09
EP3506945A4 (en) 2020-07-15
JP2023015347A (ja) 2023-01-31
WO2018045018A1 (en) 2018-03-08
EP3506945A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
JP7378106B2 (ja) ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
ES2554812T3 (es) Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
US20100063258A1 (en) Fusion protein constructs
CN112313336B (zh) 一种用于优化抗体表达的方法
CN114395584A (zh) 表达方法
AU2002217505B2 (en) Process for producing recombinant protein and fused protein
CN114450395A (zh) Lockr介导的car t细胞募集
Yang et al. Expression of active murine granulocyte‐macrophage colony‐stimulating factor in an Escherichia coli cell‐free system
EP1619208B1 (en) Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein
Zong et al. Kinetics study of the natural split Npu DnaE intein in the generation of bispecific IgG antibodies
Seki et al. A Cell-Free Gene Expression Platform for Discovering and Characterizing Stop Codon Suppressing tRNAs
JP2023553692A (ja) 標的治療のための前駆体タンパク質及びキット
CN108300725A (zh) 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用
CA3034701C (en) Production of seleno-biologics in genomically recoded organisms
EP1621556A1 (en) Method of producing target protein, fused protein and gene thereof, partial sequence protein of intein and gene thereof, expression vector and transformant
HK40007802A (en) Production of seleno-biologics in genomically recoded organisms
JP2004081199A (ja) 組換え抗体の製造方法
JP2004024095A (ja) タンパク質の生産方法、融合タンパク質及びタンパク質
LU103547B1 (en) Prokaryotic expression plasmid for recombinant feline macrophage-colony stimulating factor (fm-csf), method of constructing same and use thereof
US8030027B2 (en) Method for enhancing recombinant antibody production
CN111826365A (zh) 一种磷酸化抗原多肽、抗体及其制备方法
JPWO2004031243A1 (ja) タンパク質ポリマー及びその製造方法
Möhrle Nanobody selection from a highly variable gene library using mRNA/cDNA display
KR20140140896A (ko) 광활성 메티오닌 모사체 표지 단백질 생합성을 위한 메티오닐 tRNA 합성효소 변이체
Arauzo-Aguilera Exploring the Tat pathway for the production of disulphide-bonded recombinant proteins using CyDisCo in Escherichia coli

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007802

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20211112

Address after: Texas, USA

Applicant after: University of Texas system board

Applicant after: Harvard University

Address before: Texas, USA

Applicant before: University of Texas system board

Applicant before: PRESIDENT AND FELLOWS OF HARVARD College

Applicant before: Christopher J. Gregg

TA01 Transfer of patent application right